JP2005500389A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500389A5
JP2005500389A5 JP2003521776A JP2003521776A JP2005500389A5 JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5 JP 2003521776 A JP2003521776 A JP 2003521776A JP 2003521776 A JP2003521776 A JP 2003521776A JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
disease
soluble
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003521776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021324 external-priority patent/WO2003016467A2/en
Publication of JP2005500389A publication Critical patent/JP2005500389A/ja
Publication of JP2005500389A5 publication Critical patent/JP2005500389A5/ja
Pending legal-status Critical Current

Links

JP2003521776A 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 Pending JP2005500389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31357601P 2001-08-17 2001-08-17
US38385102P 2002-05-28 2002-05-28
PCT/US2002/021324 WO2003016467A2 (en) 2001-08-17 2002-08-14 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass

Publications (2)

Publication Number Publication Date
JP2005500389A JP2005500389A (ja) 2005-01-06
JP2005500389A5 true JP2005500389A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=26978953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521776A Pending JP2005500389A (ja) 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用

Country Status (5)

Country Link
US (1) US20040241164A1 (cg-RX-API-DMAC7.html)
EP (1) EP1429805A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005500389A (cg-RX-API-DMAC7.html)
CA (1) CA2452104A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003016467A2 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1519740A4 (en) * 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
WO2003016466A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005120571A2 (en) * 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EP1838348B1 (en) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) * 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009085200A2 (en) * 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JPWO2009104736A1 (ja) * 2008-02-22 2011-06-23 田平 武 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物
KR101706789B1 (ko) 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP2012233002A (ja) * 2012-08-03 2012-11-29 Janssen Alzheimer Immunotherapy 認知の改善における使用のためのアミロイドβ抗体
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US12345680B1 (en) 2014-03-13 2025-07-01 Innosense Corporation Modular chemiresistive sensor for real-time ethylene monitoring
US9896772B2 (en) * 2014-03-13 2018-02-20 Innosense Llc Modular chemiresistive sensor
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
SG11201703750XA (en) 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
WO2025250454A1 (en) 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta

Similar Documents

Publication Publication Date Title
Alexopoulos Vascular disease, depression, and dementia.
Yamada et al. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
JP2006519762A5 (cg-RX-API-DMAC7.html)
Kepe et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy
Waterston et al. Small deep cerebral infarcts associated with occlusive internal carotid artery disease: a hemodynamic phenomenon?
WO2007068411A3 (en) Therapeutic vaccine
WO2003015691A3 (en) RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
Fymat On dementia and other cognitive disorders
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
JP2005523335A5 (cg-RX-API-DMAC7.html)
JP2011504474A5 (cg-RX-API-DMAC7.html)
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
Li et al. Paroxysmal slow wave events are associated with cognitive impairment in patients with obstructive sleep apnea
Blasko et al. Plasma amyloid β protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy
Meador et al. Behavioral and cognitive effects of lamotrigine
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
JP2016216483A (ja) 活性化増強型抗体の効果を増大させる方法
Zhang et al. Decreased nocturnal heart rate variability and potentially related brain regions in arteriosclerotic cerebral small vessel disease
Johansson et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results
Colding‐Jørgensen et al. Visual impairment in anti‐GQ1b positive Miller Fisher syndrome
Saletu et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies
Holler et al. Camptocormia in Idiopathic Parkinson’s Disease:[[sup 123] I] β-CIT SPECT and Clinical Characteristics.
Misra et al. A comparison of clinically atypical with typical chronic inflammatory demyelinating polyradiculoneuropathy
Hornyak et al. Indications for performing polysomnography in the diagnosis and treatment of restless legs syndrome
Masdeu et al. Viral infections of the brain